Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization

Monoclonal antibodies (mAbs) and tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), which is often pathogenetically overexpressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised again...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Cell Mol Med
Main Authors: Gan, Hui K, Lappas, Martha, Cao, Diana X, Cvrljevdic, Anna, Scott, Andrew M, Johns, Terrance G
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Ltd 2009
Assuntos:
Molecular Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4516546/
https://ncbi.nlm.nih.gov/pubmed/19432811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2009.00783.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares